Interpretation Of Lisheng Pharmaceutical's 2025 Annual Report: Revenue And Profits Double, And Fruitful R&D Results
On March 24, Lisheng Pharmaceuticals announced its 2025 annual report. The company's operating income was 1.39 billion yuan, a year-on-year increase of 4.2%; the net profit attributable to the parent company was 416 million yuan, a year-on-year increase of 125.6%; the net profit after non-attribution to the parent company was 169 million yuan, a year-on-year increase of 63









